查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1592698

针对非人类灵长类动物的基于病毒载体的基因治疗市场载体类型、治疗领域； - 2024-2034 年全球产业分析、规模、份额、成长、趋势与预测

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Type of Vector, Therapeutic Area; - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 250 Pages | 商品交期: 2-10个工作天内

价格

非人类灵长类市场基于病毒载体的基因疗法 - 报告范围

TMR 关于全球基于病毒载体的非人灵长类动物基因治疗市场的报告研究了过去和当前的增长趋势以及获得 2024 年至 2034 年预测期内市场指标的宝贵见解的机会。 2034年期间全球非人灵长类病毒载体基因治疗市场的收入，以2024年为基准年，2034年为预测年。该报告还提供了2024年至2034年全球基于病毒载体的非人灵长类动物基因治疗市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解非人类灵长类动物市场基于病毒载体的基因疗法。

市场概况
2023年市场价值 2,997万美元
2034 年市场价值 9276万美元
复合年增长率 11%

该报告深入研究了全球非人类灵长类动物市场基于病毒载体的基因疗法的竞争格局。已经确定了全球基于病毒载体的非人灵长类动物基因治疗市场的主要参与者，并且对每个参与者的各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球基于病毒载体的非人灵长类动物基因治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034 年全球市场分析与预测

第 5 章：关键见解

  • 病毒载体技术的最新进展
  • 提供非人类灵长类动物临床前测试服务的领先 CRO 名单
  • PORTER 对非人类灵长类动物产业病毒载体的分析
  • 最终用户的关键入围指标
  • 非人类灵长类动物临床前研究的区域分布
  • 关键产业事件（伙伴关係、协作、产品核准、併购）
  • COVID-19 大流行对非人灵长类动物产业病毒载体的影响

第 6 章：全球市场分析与预测：按向量类型

  • 简介与定义
  • 主要发现/进展
  • 2020-2034 年向量类型市场价值预测
    • 腺病毒载体
    • 腺相关载体
    • 逆转录病毒载体
    • 慢病毒载体
    • 其他载体
  • 按向量类型分類的市场吸引力

第 7 章：全球市场分析与预测：按非人灵长类动物类型

  • 简介与定义
  • 主要发现/进展
  • 2020-2034 年非人类灵长类动物类型市场价值预测
    • 狨猴
    • 恒河猴
    • 食蟹猴
    • 其他的
  • 按非人类灵长类动物类型分類的市场吸引力

第 8 章：全球市场分析与预测：依技术分类

  • 简介与定义
  • 主要发现/进展
  • 2020-2034 年技术市场价值预测
    • 遗传性疾病
    • 传染病
    • 肿瘤疾病
    • 神经退化性疾病
    • 其他疾病
  • 技术的市场吸引力

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 各地区市场价值预测
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 按国家/地区分類的市场吸引力

第 10 章：北美市场分析与预测

  • 我们
  • 加拿大

第 11 章：欧洲市场分析与预测

  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区

第 12 章：亚太市场分析与预测

  • 中国
  • 印度
  • 日本
  • 澳洲和纽西兰
  • 亚太地区其他地区

第 13 章：拉丁美洲市场分析与预测

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第 14 章：中东和非洲市场分析与预测

  • 海湾合作委员会
  • 南非
  • 中东和非洲其他地区

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 公司简介
    • CRISPR Therapeutics AG
    • Voyager Therapeutics, Inc.
    • Sarepta Therapeutics, Inc.
    • Neuracle Genetics
    • Beacon Therapeutics
    • REGENXBIO Inc.
    • 4D Molecular Therapeutics
    • Rocket Pharmaceuticals, Inc.
Product Code: TMRGL86394

Viral Vectors-Based Gene Therapy for Non-Human Primates Market - Scope of Report

TMR's report on the global viral vectors-based gene therapy for non-human primates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global viral vectors-based gene therapy for non-human primates market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global viral vectors-based gene therapy for non-human primates market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the viral vectors-based gene therapy for non-human primates market.

Market Snapshot
Market Value in 2023US$ 29.97 Mn
Market Value in 2034US$ 92.76 Mn
CAGR11%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global viral vectors-based gene therapy for non-human primates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global viral vectors-based gene therapy for non-human primates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global viral vectors-based gene therapy for non-human primates market.

The report delves into the competitive landscape of the global viral vectors-based gene therapy for non-human primates market. Key players operating in the global viral vectors-based gene therapy for non-human primates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global viral vectors-based gene therapy for non-human primates market profiled in this report.

Key Questions Answered in Global viral vectors-based gene therapy for non-human primates Market Report:

  • What is the sales/revenue generated by viral vectors-based gene therapy for non-human primates across all regions during the forecast period?
  • What are the opportunities in the global viral vectors-based gene therapy for non-human primates market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Viral Vectors-Based Gene Therapy for Non-Human Primates Market - Research Objectives and Research Approach

The comprehensive report on the global viral vectors-based gene therapy for non-human primates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global viral vectors-based gene therapy for non-human primates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global viral vectors-based gene therapy for non-human primates market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Viral Vectors-based Gene Therapy for Non-human Primates Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Vector Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Recent Advancements in Viral Vectors Technology
  • 5.2. List of Leading CROs offering Non-human Primates based Preclinical Testing Services
  • 5.3. PORTER's Analysis on Viral Vectors for Non-human Primates Industry
  • 5.4. Key Shortlisting Metrics for End-users
  • 5.5. Regional Distribution of Non-human Primate Preclinical Studies
  • 5.6. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
  • 5.7. Impact of COVID-19 Pandemic on Viral Vectors for Non-human Primates Industry

6. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Vector Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Vector Type, 2020-2034
    • 6.3.1. Adenoviral Vectors
    • 6.3.2. Adeno-associated Vectors
    • 6.3.3. Retroviral Vectors
    • 6.3.4. Lentiviral Vectors
    • 6.3.5. Other Vectors
  • 6.4. Market Attractiveness By Vector Type

7. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primate

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
    • 7.3.1. Marmosets
    • 7.3.2. Rhesus Macaques
    • 7.3.3. Cynomolgus Monkey
    • 7.3.4. Others
  • 7.4. Market Attractiveness By Type of Non-human Primate

8. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Technology, 2020-2034
    • 8.3.1. Genetic Disorders
    • 8.3.2. Infectious Diseases
    • 8.3.3. Oncological Disorders
    • 8.3.4. Neurodegenerative Disorders
    • 8.3.5. Other Disorders
  • 8.4. Market Attractiveness By Technology

9. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Vector Type, 2020-2034
    • 10.2.1. Adenoviral Vectors
    • 10.2.2. Adeno-associated Vectors
    • 10.2.3. Retroviral Vectors
    • 10.2.4. Lentiviral Vectors
    • 10.2.5. Other Vectors
  • 10.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
    • 10.3.1. Marmosets
    • 10.3.2. Rhesus Macaques
    • 10.3.3. Cynomolgus Monkey
    • 10.3.4. Others
  • 10.4. Market Value Forecast By Technology, 2020-2034
    • 10.4.1. Genetic Disorders
    • 10.4.2. Infectious Diseases
    • 10.4.3. Oncological Disorders
    • 10.4.4. Neurodegenerative Disorders
    • 10.4.5. Other Disorders
  • 10.5. Market Value Forecast By Country, 2020-2034
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Vector Type
    • 10.6.2. By Type of Non-human Primate
    • 10.6.3. By Technology
    • 10.6.4. By Country

11. Europe Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Vector Type, 2020-2034
    • 11.2.1. Adenoviral Vectors
    • 11.2.2. Adeno-associated Vectors
    • 11.2.3. Retroviral Vectors
    • 11.2.4. Lentiviral Vectors
    • 11.2.5. Other Vectors
  • 11.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
    • 11.3.1. Marmosets
    • 11.3.2. Rhesus Macaques
    • 11.3.3. Cynomolgus Monkey
    • 11.3.4. Others
  • 11.4. Market Value Forecast By Technology, 2020-2034
    • 11.4.1. Genetic Disorders
    • 11.4.2. Infectious Diseases
    • 11.4.3. Oncological Disorders
    • 11.4.4. Neurodegenerative Disorders
    • 11.4.5. Other Disorders
  • 11.5. Market Value Forecast By Country, 2020-2034
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Vector Type
    • 11.6.2. By Type of Non-human Primate
    • 11.6.3. By Technology
    • 11.6.4. By Country

12. Asia Pacific Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Vector Type, 2020-2034
    • 12.2.1. Adenoviral Vectors
    • 12.2.2. Adeno-associated Vectors
    • 12.2.3. Retroviral Vectors
    • 12.2.4. Lentiviral Vectors
    • 12.2.5. Other Vectors
  • 12.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
    • 12.3.1. Marmosets
    • 12.3.2. Rhesus Macaques
    • 12.3.3. Cynomolgus Monkey
    • 12.3.4. Others
  • 12.4. Market Value Forecast By Technology, 2020-2034
    • 12.4.1. Genetic Disorders
    • 12.4.2. Infectious Diseases
    • 12.4.3. Oncological Disorders
    • 12.4.4. Neurodegenerative Disorders
    • 12.4.5. Other Disorders
  • 12.5. Market Value Forecast By Country, 2020-2034
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Vector Type
    • 12.6.2. By Type of Non-human Primate
    • 12.6.3. By Technology
    • 12.6.4. By Country

13. Latin America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Vector Type, 2020-2034
    • 13.2.1. Adenoviral Vectors
    • 13.2.2. Adeno-associated Vectors
    • 13.2.3. Retroviral Vectors
    • 13.2.4. Lentiviral Vectors
    • 13.2.5. Other Vectors
  • 13.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
    • 13.3.1. Marmosets
    • 13.3.2. Rhesus Macaques
    • 13.3.3. Cynomolgus Monkey
    • 13.3.4. Others
  • 13.4. Market Value Forecast By Technology, 2020-2034
    • 13.4.1. Genetic Disorders
    • 13.4.2. Infectious Diseases
    • 13.4.3. Oncological Disorders
    • 13.4.4. Neurodegenerative Disorders
    • 13.4.5. Other Disorders
  • 13.5. Market Value Forecast By Country, 2020-2034
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Vector Type
    • 13.6.2. By Type of Non-human Primate
    • 13.6.3. By Technology
    • 13.6.4. By Country

14. Middle East & Africa Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Vector Type, 2020-2034
    • 14.2.1. Adenoviral Vectors
    • 14.2.2. Adeno-associated Vectors
    • 14.2.3. Retroviral Vectors
    • 14.2.4. Lentiviral Vectors
    • 14.2.5. Other Vectors
  • 14.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
    • 14.3.1. Marmosets
    • 14.3.2. Rhesus Macaques
    • 14.3.3. Cynomolgus Monkey
    • 14.3.4. Others
  • 14.4. Market Value Forecast By Technology, 2020-2034
    • 14.4.1. Genetic Disorders
    • 14.4.2. Infectious Diseases
    • 14.4.3. Oncological Disorders
    • 14.4.4. Neurodegenerative Disorders
    • 14.4.5. Other Disorders
  • 14.5. Market Value Forecast By Country, 2020-2034
    • 14.5.1. GCC
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Vector Type
    • 14.6.2. By Type of Non-human Primate
    • 14.6.3. By Technology
    • 14.6.4. By Country

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Company Profiles
    • 15.2.1. CRISPR Therapeutics AG
      • 15.2.1.1. Company Overview
      • 15.2.1.2. Financial Overview
      • 15.2.1.3. Product Portfolio
      • 15.2.1.4. Business Strategies
      • 15.2.1.5. Recent Developments
    • 15.2.2. Voyager Therapeutics, Inc.
      • 15.2.2.1. Company Overview
      • 15.2.2.2. Financial Overview
      • 15.2.2.3. Product Portfolio
      • 15.2.2.4. Business Strategies
      • 15.2.2.5. Recent Developments
    • 15.2.3. Sarepta Therapeutics, Inc.
      • 15.2.3.1. Company Overview
      • 15.2.3.2. Financial Overview
      • 15.2.3.3. Product Portfolio
      • 15.2.3.4. Business Strategies
      • 15.2.3.5. Recent Developments
    • 15.2.4. Neuracle Genetics
      • 15.2.4.1. Company Overview
      • 15.2.4.2. Financial Overview
      • 15.2.4.3. Product Portfolio
      • 15.2.4.4. Business Strategies
      • 15.2.4.5. Recent Developments
    • 15.2.5. Beacon Therapeutics
      • 15.2.5.1. Company Overview
      • 15.2.5.2. Financial Overview
      • 15.2.5.3. Product Portfolio
      • 15.2.5.4. Business Strategies
      • 15.2.5.5. Recent Developments
    • 15.2.6. REGENXBIO Inc.
      • 15.2.6.1. Company Overview
      • 15.2.6.2. Financial Overview
      • 15.2.6.3. Product Portfolio
      • 15.2.6.4. Business Strategies
      • 15.2.6.5. Recent Developments
    • 15.2.7. 4D Molecular Therapeutics
      • 15.2.7.1. Company Overview
      • 15.2.7.2. Financial Overview
      • 15.2.7.3. Product Portfolio
      • 15.2.7.4. Business Strategies
      • 15.2.7.5. Recent Developments
    • 15.2.8. Rocket Pharmaceuticals, Inc.
      • 15.2.8.1. Company Overview
      • 15.2.8.2. Financial Overview
      • 15.2.8.3. Product Portfolio
      • 15.2.8.4. Business Strategies
      • 15.2.8.5. Recent Developments

Viral Vectors-Based Gene Therapy for Non-Human Primates Market

Viral Vectors-Based Gene Therapy for Non-Human Primates Industry

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Size

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Share

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Growth

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Analysis

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Demand

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Forecast

Viral Vectors-Based Gene Therapy for Non-Human Primates Market Trends

List of Tables

  • Table 01: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
  • Table 02: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
  • Table 03: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
  • Table 04: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 05: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
  • Table 08: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 09: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
  • Table 10: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 11: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
  • Table 13: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
  • Table 14: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
  • Table 15: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 16: Asia Pacific Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
  • Table 18: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
  • Table 19: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
  • Table 20: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 21: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
  • Table 23: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
  • Table 24: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
  • Table 25: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 26: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Vector, 2020-2034
  • Table 28: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Type of Non-human Primate, 2020-2034
  • Table 29: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
  • Table 30: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, By End-user, 2020-2034

List of Figures

  • Figure 01: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 02: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by Type of Vector, 2023
  • Figure 03: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by Type of Non-human Primate, 2023
  • Figure 04: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by Therapeutic Area, 2023
  • Figure 05: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, by End-user, 2023
  • Figure 06: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share, By Region, 2023
  • Figure 07: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
  • Figure 08: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Vector, 2023
  • Figure 09: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Vector, 2034
  • Figure 10: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
  • Figure 11: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Adenoviral Vectors, 2020-2034
  • Figure 12: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Adenoviral Vectors, 2023 and 2034
  • Figure 13: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Adeno-associated Vectors, 2020-2034
  • Figure 14: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Adeno-associated Vectors, 2023 and 2034
  • Figure 15: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Retroviral Vectors, 2020-2034
  • Figure 16: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Retroviral Vectors, 2023 and 2034
  • Figure 17: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Lentiviral Vectors, 2020-2034
  • Figure 18: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Lentiviral Vectors, 2023 and 2034
  • Figure 19: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Other Vectors, 2020-2034
  • Figure 20: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Other Vectors, 2023 and 2034
  • Figure 21: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
  • Figure 22: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Non-human Primate, 2023
  • Figure 23: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Type of Non-human Primate, 2034
  • Figure 24: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
  • Figure 25: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Marmosets, 2020-2034
  • Figure 26: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Marmosets, 2023 and 2034
  • Figure 27: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Rhesus Macaques, 2020-2034
  • Figure 28: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Rhesus Macaques, 2023 and 2034
  • Figure 29: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Cynomolgus Monkey, 2020-2034
  • Figure 30: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Cynomolgus Monkey, 2023 and 2034
  • Figure 31: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Others, 2020-2034
  • Figure 32: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Others, 2023 and 2034
  • Figure 33: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 34: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Therapeutic Area, 2023
  • Figure 35: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Therapeutic Area, 2034
  • Figure 36: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Derivatives Type, 2024-2034
  • Figure 37: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Genetic Disorders, 2020-2034
  • Figure 38: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Genetic Disorders, 2023 and 2034
  • Figure 39: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Infectious Diseases, 2020-2034
  • Figure 40: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Infectious Diseases, 2023 and 2034
  • Figure 41: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Oncological Disorders, 2020-2034
  • Figure 42: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Oncological Disorders, 2023 and 2034
  • Figure 43: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Neurodegenerative Disorders, 2020-2034
  • Figure 44: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Neurodegenerative Disorders, 2023 and 2034
  • Figure 45: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Other Disorders, 2020-2034
  • Figure 46: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Other Disorders, 2023 and 2034
  • Figure 47: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
  • Figure 48: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, By End-user, 2023
  • Figure 49: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, By End-user, 2034
  • Figure 50: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 51: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2020-2034
  • Figure 52: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Pharmaceutical and Biotechnology Companies, 2023 and 2034
  • Figure 53: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Contract Research Organizations, 2020-2034
  • Figure 54: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Contract Research Organizations, 2023 and 2034
  • Figure 55: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn), by Academic and Research Institutes, 2020-2034
  • Figure 56: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Academic and Research Institutes, 2023 and 2034
  • Figure 57: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 58: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Region, 2023
  • Figure 59: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Share Analysis, by Region, 2034
  • Figure 60: Global Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 61: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 62: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 63: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 64: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
  • Figure 65: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
  • Figure 66: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
  • Figure 67: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
  • Figure 68: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 69: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 70: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
  • Figure 71: North America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 72: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 73: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 74: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 75: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
  • Figure 76: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
  • Figure 77: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
  • Figure 78: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
  • Figure 79: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 80: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 81: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
  • Figure 82: Europe - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 83: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 84: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 85: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 86: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
  • Figure 87: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
  • Figure 88: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
  • Figure 89: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
  • Figure 90: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 91: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 92: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
  • Figure 93: Asia Pacific - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 94: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 95: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 96: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 97: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
  • Figure 98: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
  • Figure 99: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
  • Figure 100: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
  • Figure 101: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 102: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 103: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
  • Figure 104: Latin America - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 105: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 106: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 107: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 108: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Vector, 2023 and 2034
  • Figure 109: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Vector, 2024-2034
  • Figure 110: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Type of Non-human Primate, 2023 and 2034
  • Figure 111: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Type of Non-human Primate, 2024-2034
  • Figure 112: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 113: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 114: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Value (US$ Mn) Share Analysis, By End-user, 2023 and 2034
  • Figure 115: Middle East & Africa - Viral Vectors-based Gene Therapy for Non-human Primates Market Attractiveness Analysis, By End-user, 2024-2034